1 source filed · EN 1
From a Capgemini Research Institute survey of biopharma R&D leaders: 86% expect AI to reshape R&D but 63% lack the data maturity; 76% anticipate new ways of working but fewer than half feel ready; 71% are defining enterprise AI strategies, 8% are implementing them.
~84%share of 270 pharma and MedTech processes Capgemini rates as 'agentifiable'
1 source filed · EN 1
67% of executives expect physical AI to transform their industry (US 73%, Europe 64%, APAC 67%); 64% expect it to become a critical driver of competitiveness.
79% / 27%organizations engaging with physical AI / deploying or scaling it
1 source filed · EN 1
Top-performing enterprises process over 90 percent of orders without human intervention; the rest need manual handling for pricing discrepancies, customer-specific terms, incomplete orders, stock allocation, credit risk and compliance.
over 90 percentshare of orders top-performing enterprises already process without human intervention (per Capgemini)